SVP & CFO of Alexion Pharmaceuticals Inc. (ALXN, Financial) Vikas Sinha sells 10,000 shares of ALXN on 12/10/2009 at an average price of $46 a share.
Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional. Alexion Pharmaceuticals Inc. has a market cap of $4.14 billion; its shares were traded at around $46.77 with a P/E ratio of 55.02 and P/S ratio of 15.99.
ALXN is in the portfolios of Bruce Kovner of Caxton Associates.
Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional. Alexion Pharmaceuticals Inc. has a market cap of $4.14 billion; its shares were traded at around $46.77 with a P/E ratio of 55.02 and P/S ratio of 15.99.
ALXN is in the portfolios of Bruce Kovner of Caxton Associates.
CEO Recent Trades:
- Sell:: CEO Leonard Bell sold 37,810 shares of ALXN stock on 12/04/2009 at the average price of 45.24, the price of the stock has increased by 3.38% since
- Sell:: CEO Leonard Bell sold 18,505 shares of ALXN stock on 11/05/2009 at the average price of 44.91, the price of the stock has increased by 4.14% since
- Sell:: CEO Leonard Bell sold 20,400 shares of ALXN stock on 11/02/2009 at the average price of 43.82, the price of the stock has increased by 6.73% since
- Sell:: CEO Leonard Bell sold 18,905 shares of ALXN stock on 10/12/2009 at the average price of 44.91, the price of the stock has increased by 4.14% since
- Sell:: CEO Leonard Bell sold 20,000 shares of ALXN stock on 10/01/2009 at the average price of 43.76, the price of the stock has increased by 6.88% since
CFO Recent Trades:
- Sell:: SVP & CFO Vikas Sinha sold 1,833 shares of ALXN stock on 09/22/2009 at the average price of 46.27, the price of the stock has increased by 1.08% since
- Sell:: SVP & CFO Vikas Sinha sold 397 shares of ALXN stock on 07/16/2009 at the average price of 38.96, the price of the stock has increased by 20.05% since
- Sell:: SVP & CFO Vikas Sinha sold 318 shares of ALXN stock on 07/10/2009 at the average price of 36.93, the price of the stock has increased by 26.65% since
Directors and Officers Recent Trades:
- Sell:: Director R Douglas Norby sold 15,000 shares of ALXN stock on 11/03/2009 at the average price of 43.94, the price of the stock has increased by 6.44% since
- Sell:: Director Larry Mathis sold 13,000 shares of ALXN stock on 10/27/2009 at the average price of 48.42, the price of the stock has decreased by 3.41% since
- Sell:: EVP & Head of Research Stephen P Squinto sold 45,800 shares of ALXN stock on 08/24/2009 at the average price of 45, the price of the stock has increased by 3.93% since
- Sell:: Director R Douglas Norby sold 17,000 shares of ALXN stock on 08/24/2009 at the average price of 45, the price of the stock has increased by 3.93% since
- Sell:: EVP & Head of Research Stephen P Squinto sold 4,200 shares of ALXN stock on 08/04/2009 at the average price of 45, the price of the stock has increased by 3.93% since
